NO320363B1 - Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer. - Google Patents

Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer. Download PDF

Info

Publication number: NO320363B1
Authority: NO; Norway
Prior art keywords: preparation according; fat emulsion; val; peptide; treatment
Prior art date: 1995-07-05

Application number

NO19980013A

Other languages

English (en)

Norwegian (no)

Other versions

NO980013D0 (no

NO980013L (no

Inventor

Dana Elias

Irun R Cohen

Meir Shinitzky

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-05

Filing date

1998-01-02

Publication date

2005-11-28

1998-01-02 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1998-01-02 Publication of NO980013D0 publication Critical patent/NO980013D0/no

1998-02-19 Publication of NO980013L publication Critical patent/NO980013L/no

2005-11-28 Publication of NO320363B1 publication Critical patent/NO320363B1/no

Links

210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 53
239000002960 lipid emulsion Substances 0.000 title claims abstract description 38
208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 20
230000001404 mediated effect Effects 0.000 title claims abstract description 18
238000002360 preparation method Methods 0.000 title claims description 36
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 81
229940028435 intralipid Drugs 0.000 claims abstract description 44
102000004127 Cytokines Human genes 0.000 claims abstract description 36
108090000695 Cytokines Proteins 0.000 claims abstract description 36
239000000427 antigen Substances 0.000 claims abstract description 27
102000036639 antigens Human genes 0.000 claims abstract description 24
108091007433 antigens Proteins 0.000 claims abstract description 24
201000010099 disease Diseases 0.000 claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
230000001225 therapeutic effect Effects 0.000 claims abstract description 17
230000002757 inflammatory effect Effects 0.000 claims abstract description 12
230000008506 pathogenesis Effects 0.000 claims abstract description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
230000004044 response Effects 0.000 claims description 17
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 17
239000003549 soybean oil Substances 0.000 claims description 16
235000012424 soybean oil Nutrition 0.000 claims description 16
150000003904 phospholipids Chemical class 0.000 claims description 15
102000004196 processed proteins & peptides Human genes 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 14
239000008223 sterile water Substances 0.000 claims description 14
108090000978 Interleukin-4 Proteins 0.000 claims description 12
241000196324 Embryophyta Species 0.000 claims description 11
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 10
239000008344 egg yolk phospholipid Substances 0.000 claims description 10
229940068998 egg yolk phospholipid Drugs 0.000 claims description 10
108010002350 Interleukin-2 Proteins 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
201000006417 multiple sclerosis Diseases 0.000 claims description 7
230000009467 reduction Effects 0.000 claims description 7
150000003626 triacylglycerols Chemical class 0.000 claims description 7
239000003963 antioxidant agent Substances 0.000 claims description 6
230000003078 antioxidant effect Effects 0.000 claims description 6
102000002322 Egg Proteins Human genes 0.000 claims description 4
108010000912 Egg Proteins Proteins 0.000 claims description 4
235000013345 egg yolk Nutrition 0.000 claims description 4
210000002969 egg yolk Anatomy 0.000 claims description 4
JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 3
102100037850 Interferon gamma Human genes 0.000 claims description 3
108010074328 Interferon-gamma Proteins 0.000 claims description 3
239000012888 bovine serum Substances 0.000 claims description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
244000068988 Glycine max Species 0.000 claims description 2
235000010469 Glycine max Nutrition 0.000 claims description 2
101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
229960001295 tocopherol Drugs 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
235000010384 tocopherol Nutrition 0.000 claims description 2
239000011732 tocopherol Substances 0.000 claims description 2
239000000811 xylitol Substances 0.000 claims description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
229960002675 xylitol Drugs 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 abstract description 27
239000000839 emulsion Substances 0.000 abstract description 21
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 94
241000699670 Mus sp. Species 0.000 description 45
210000004027 cell Anatomy 0.000 description 14
239000003981 vehicle Substances 0.000 description 13
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
150000002632 lipids Chemical class 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
108010062580 Concanavalin A Proteins 0.000 description 11
102000004388 Interleukin-4 Human genes 0.000 description 11
206010012601 diabetes mellitus Diseases 0.000 description 10
206010061218 Inflammation Diseases 0.000 description 9
241000700159 Rattus Species 0.000 description 9
201000002491 encephalomyelitis Diseases 0.000 description 9
230000004054 inflammatory process Effects 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
108010058432 Chaperonin 60 Proteins 0.000 description 7
102000006303 Chaperonin 60 Human genes 0.000 description 7
102000047918 Myelin Basic Human genes 0.000 description 7
101710107068 Myelin basic protein Proteins 0.000 description 7
230000005867 T cell response Effects 0.000 description 7
230000001363 autoimmune Effects 0.000 description 7
235000019197 fats Nutrition 0.000 description 7
230000004913 activation Effects 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
235000016709 nutrition Nutrition 0.000 description 6
230000035764 nutrition Effects 0.000 description 6
210000004989 spleen cell Anatomy 0.000 description 6
230000002269 spontaneous effect Effects 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
206010033799 Paralysis Diseases 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
230000009696 proliferative response Effects 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
102000008214 Glutamate decarboxylase Human genes 0.000 description 4
108091022930 Glutamate decarboxylase Proteins 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
210000004153 islets of langerhan Anatomy 0.000 description 3
238000011694 lewis rat Methods 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
230000003614 tolerogenic effect Effects 0.000 description 3
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
-1 comprising a stable Substances 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000000034 method Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000008569 process Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
206010043778 thyroiditis Diseases 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000615866 Antho Species 0.000 description 1
244000186140 Asperula odorata Species 0.000 description 1
241000587155 Athene Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
235000008526 Galium odoratum Nutrition 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000445359 Mus haussa Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000006470 autoimmune attack Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
229950010555 avridine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000001904 diabetogenic effect Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001712 encephalitogenic effect Effects 0.000 description 1
239000012645 endogenous antigen Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000006749 inflammatory damage Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rehabilitation Therapy (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Marine Sciences & Fisheries (AREA)

NO19980013A 1995-07-05 1998-01-02 Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer. NO320363B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL11445895A IL114458A0 (en)	1995-07-05	1995-07-05	Therapeutic preparations for treatment of T cell mediated diseases
PCT/US1996/011373 WO1997002016A1 (fr)	1995-07-05	1996-07-02	Preparations et procedes de traitments de maladies mediees par les lymphocytes t

Publications (3)

Publication Number	Publication Date
NO980013D0 NO980013D0 (no)	1998-01-02
NO980013L NO980013L (no)	1998-02-19
NO320363B1 true NO320363B1 (no)	2005-11-28

Family

ID=11067727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19980013A NO320363B1 (no)	1995-07-05	1998-01-02	Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer.

Country Status (22)

Country	Link
EP (1)	EP0837672B9 (fr)
JP (2)	JP4357595B2 (fr)
KR (1)	KR100435040B1 (fr)
CN (1)	CN1102382C (fr)
AT (1)	ATE254451T1 (fr)
AU (1)	AU714970B2 (fr)
CA (1)	CA2226013C (fr)
CZ (1)	CZ298A3 (fr)
DE (1)	DE69630787T2 (fr)
DK (1)	DK0837672T3 (fr)
ES (1)	ES2211963T3 (fr)
HR (1)	HRP960315A2 (fr)
HU (1)	HU223081B1 (fr)
IL (2)	IL114458A0 (fr)
MX (1)	MX9800190A (fr)
NO (1)	NO320363B1 (fr)
PT (1)	PT837672E (fr)
SI (1)	SI0837672T1 (fr)
UY (1)	UY24275A1 (fr)
WO (1)	WO1997002016A1 (fr)
YU (1)	YU40796A (fr)
ZA (1)	ZA965666B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en)	1996-11-29	2000-02-08	The Regents Of The University Of California	Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
IL142536A0 (en) *	2001-04-11	2002-03-10	Yeda Res & Dev	Carriers for therapeutic preparations for treatment of t-cell mediated diseases
WO2003096967A2 (fr)	2002-05-21	2003-11-27	Yeda Research And Development Co. Ltd.	Vaccins d'adn codant des proteines de choc thermique
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (fr) *	2003-05-12	2004-11-18	Peptor Ltd.	Compositions et procedes de modulation d'epitopes de hsp60 specifiques
WO2005048914A2 (fr) *	2003-11-24	2005-06-02	Yeda Research & Development Co. Ltd.	Vaccins d'adn codant pour des fragments de peptide hsp60 permettant de traiter les maladies auto-immunes
EP1835933A4 (fr)	2005-01-04	2015-01-07	Yeda Res & Dev	Hsp60, peptides hsp60 et vaccins a base de lymphocytes t pour immunomodulation
EP1945246A4 (fr)	2005-09-22	2009-03-11	Irun R Cohen	Fragments immunogènes de domaines constants du récepteur de lymphocytes t et peptides dérivés de ceux-ci
JP2019523633A (ja) *	2016-04-29	2019-08-29	アライムファーマシューティカルズ，インコーポレーテッド	組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395394A (en) *	1979-10-26	1983-07-26	Pfizer Inc.	Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) *	1981-09-04	1985-07-31	Yeda Res & Dev	Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

1995
- 1995-07-05 IL IL11445895A patent/IL114458A0/xx unknown
1996
- 1996-07-02 IL IL12275596A patent/IL122755A/en not_active IP Right Cessation
- 1996-07-02 CZ CZ982A patent/CZ298A3/cs unknown
- 1996-07-02 ES ES96924371T patent/ES2211963T3/es not_active Expired - Lifetime
- 1996-07-02 DK DK96924371T patent/DK0837672T3/da active
- 1996-07-02 MX MX9800190A patent/MX9800190A/es unknown
- 1996-07-02 KR KR10-1998-0700036A patent/KR100435040B1/ko not_active Expired - Fee Related
- 1996-07-02 SI SI9630662T patent/SI0837672T1/xx unknown
- 1996-07-02 DE DE69630787T patent/DE69630787T2/de not_active Expired - Lifetime
- 1996-07-02 CA CA2226013A patent/CA2226013C/fr not_active Expired - Lifetime
- 1996-07-02 CN CN96196402A patent/CN1102382C/zh not_active Expired - Lifetime
- 1996-07-02 JP JP50531797A patent/JP4357595B2/ja not_active Expired - Lifetime
- 1996-07-02 HU HU9802834A patent/HU223081B1/hu active IP Right Grant
- 1996-07-02 AU AU64844/96A patent/AU714970B2/en not_active Expired
- 1996-07-02 PT PT96924371T patent/PT837672E/pt unknown
- 1996-07-02 AT AT96924371T patent/ATE254451T1/de active
- 1996-07-02 WO PCT/US1996/011373 patent/WO1997002016A1/fr not_active Ceased
- 1996-07-02 EP EP96924371A patent/EP0837672B9/fr not_active Expired - Lifetime
- 1996-07-04 ZA ZA965666A patent/ZA965666B/xx unknown
- 1996-07-04 HR HR114458A patent/HRP960315A2/hr not_active Application Discontinuation
- 1996-07-05 UY UY24275A patent/UY24275A1/es unknown
- 1996-07-05 YU YU40796A patent/YU40796A/sh unknown
1998
- 1998-01-02 NO NO19980013A patent/NO320363B1/no not_active IP Right Cessation
2009
- 2009-06-15 JP JP2009141914A patent/JP2009242412A/ja active Pending

Also Published As

Publication number	Publication date
SI0837672T1 (en)	2004-04-30
HU223081B1 (hu)	2004-03-29
PT837672E (pt)	2004-03-31
DE69630787T2 (de)	2004-10-07
UY24275A1 (es)	2000-12-29
CZ298A3 (cs)	1998-06-17
AU6484496A (en)	1997-02-05
JP4357595B2 (ja)	2009-11-04
YU40796A (sh)	1998-11-05
ATE254451T1 (de)	2003-12-15
IL122755A0 (en)	1998-08-16
JP2009242412A (ja)	2009-10-22
MX9800190A (es)	1998-04-30
DK0837672T3 (da)	2004-03-22
ES2211963T3 (es)	2004-07-16
EP0837672A4 (fr)	1999-01-27
NO980013D0 (no)	1998-01-02
CN1102382C (zh)	2003-03-05
DE69630787D1 (de)	2003-12-24
IL122755A (en)	2004-07-25
HRP960315A2 (en)	1998-02-28
JPH11508899A (ja)	1999-08-03
CA2226013C (fr)	2012-09-18
HUP9802834A2 (hu)	1999-03-29
EP0837672A1 (fr)	1998-04-29
EP0837672B9 (fr)	2005-06-15
ZA965666B (en)	1997-01-27
NO980013L (no)	1998-02-19
AU714970B2 (en)	2000-01-13
EP0837672B1 (fr)	2003-11-19
CN1193907A (zh)	1998-09-23
WO1997002016A1 (fr)	1997-01-23
CA2226013A1 (fr)	1997-01-23
HUP9802834A3 (en)	2001-08-28
KR19990028738A (ko)	1999-04-15
KR100435040B1 (ko)	2004-08-18
IL114458A0 (en)	1995-11-27

Legal Events

Date	Code	Title	Description
2016-07-11	MK1K	Patent expired

Publication	Publication Date	Title
JP2009242412A (ja)	2009-10-22	Ｔ細胞介在の病気を治療するための製剤と方法
CA2263816C (fr)	2008-12-30	Methode de reduction de la gravite d'une reaction de l'hote contre le greffon par regulation negative de l'autoimmunite vis-a-vis de hsp60
CN1327898C (zh)	2007-07-25	用作抗原载体的抗炎性脂肪醇和脂肪酸酯
US20010007758A1 (en)	2001-07-12	Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
MXPA98000190A (en)	1998-04-01	Preparations and methods for the treatment of medium diseases by cellula
WO1997002016A9 (fr)	1997-02-20	Preparations et procedes de traitments de maladies mediees par les lymphocytes t
Rolland et al.	2000	Allergen immunotherapy: current and new therapeutic strategies
US20030190323A1 (en)	2003-10-09	Preparations and methods for the treatment of T cell mediated diseases
Benson et al.	1997	The role of clonal deletion and anergy in oral tolerance
US6488933B2 (en)	2002-12-03	Preparations for the treatment of T cell mediated diseases
JP3905126B2 (ja)	2007-04-18	Ｔ細胞媒介疾患の治療の効力を検出又は監視する方法
Kato et al.	1999	The influence of initial exposure timing to β-lactoglobulin on oral tolerance induction
Hafler et al.	1995	Antigen-specific therapies for the treatment of autoimmune diseases
RU2731509C1 (ru)	2020-09-03	Способ получения аллергоида на основе пчелиного яда для проведения аллерген-специфической иммунотерапии
HAFLER et al.	1996	Oral Tolerance for the Treatment
WO2021162563A1 (fr)	2021-08-19	Lipopolysaccharides pour le traitement d'allergies alimentaires
DAVID	1996	Oral Tolerance for the Treatment of Autoimmune Disease
HAFLER et al.	1996	I. OVERVIEW OF HUMAN AUTOIMMUNE DISEASE
Hafler¹ et al.	1996	Antigen-specific therapies for the treatment
Hafter et al.	1996	Oral Tolerance for the Treatment of Autoimmune Disease